An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
Public ClinicalTrials.gov record NCT00057213. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)
Study identification
- NCT ID
- NCT00057213
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 367 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2003
- Primary completion
- Mar 31, 2007
- Completion
- Mar 31, 2007
- Last update posted
- Apr 15, 2015
2003 – 2007
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Peoria | Arizona | 85381 - 4828 | — |
| GSK Investigational Site | Scottsdale | Arizona | 85251 | — |
| GSK Investigational Site | Garden Grove | California | 92845 | — |
| GSK Investigational Site | Irvine | California | 92618 | — |
| GSK Investigational Site | National City | California | 91950 | — |
| GSK Investigational Site | Miami | Florida | 33173 | — |
| GSK Investigational Site | Winter Park | Florida | 32789 | — |
| GSK Investigational Site | Springfield | Illinois | 62702 | — |
| GSK Investigational Site | Terre Haute | Indiana | 47802 | — |
| GSK Investigational Site | Florence | Kentucky | 41042 | — |
| GSK Investigational Site | Brockton | Massachusetts | 2301 | — |
| GSK Investigational Site | New York | New York | 10021 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27514 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27609 | — |
| GSK Investigational Site | Lyndhurst | Ohio | 44124 | — |
| GSK Investigational Site | Eugene | Oregon | 97401 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19106 | — |
| GSK Investigational Site | Austin | Texas | 78756 | — |
| GSK Investigational Site | Galveston | Texas | 77555 | — |
| GSK Investigational Site | Lake Jackson | Texas | 77566 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00057213, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2015 · Synced Sep 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00057213 live on ClinicalTrials.gov.